Joint Research on Treating Autoantibody-Related Diseases with BAR-T Cells
First written in FY2020-Q1. 2 of 4 entries say "Advanced", first in FY2020-Q3. Latest entry: FY2023-Q1.
No other company in this theme has enough history to compare yet.
- FY2023-Q1DroppedAnnual report
「The Company entered into a joint research agreement with Kyoto Prefectural University of Medicine on 5 November 2019 for the practical application of a specific B-cell depletion therapy using immune cells genetically engineered with a novel chimeric receptor (a B-cell antibody receptor, or BAR) (BAR-T cells) to treat conditions caused by the production of autoantibodies, and conducted the joint research. However, because several issues arose in the nonclinical studies and resolving them was expected to take considerable time, the parties comprehensively considered their future research plans and other matters and recently agreed to terminate the joint research.」
The joint research on BAR-T cells was terminated because of issues in the nonclinical studies and the time required to resolve them. The Company plans to use the results obtained in research and development of new regenerative medicine products and other products while continuing its basic research. - FY2022AdvancedAnnual report
「In October 2019, the Company entered into a joint research agreement with Kyoto Prefectural University of Medicine for the practical application of a specific B-cell depletion method using immune cells genetically engineered with a novel chimeric receptor (a B-cell antibody receptor, or BAR) (BAR-T cells) to treat conditions caused by the production of autoantibodies, and is conducting nonclinical pharmacology studies to investigate the development potential of BAR-T cells.」
The BAR-T joint research progressed from the planning stage for research funding to the stage of conducting nonclinical pharmacology studies to investigate development potential. - FY2020-Q3AdvancedAnnual report
「Expenses related to the research and development of BAR-T technology in a joint research project with Kyoto Prefectural University of Medicine」
Research and development expenses for the joint research on BAR-T technology were stated as a use of proceeds from the 16th Stock Acquisition Rights. - FY2020-Q1First statedAnnual report
「In November 2019, we entered into a joint research agreement with Kyoto Prefectural University of Medicine to commercialize a method for selectively removing B cells using immune cells genetically modified with a new chimeric receptor, called a B-cell antibody receptor (BAR), or BAR-T cells, for diseases caused by the production of autoantibodies, and jointly filed a patent application for the technology.」
The Company signed a joint research agreement with Kyoto Prefectural University of Medicine to commercialize selective B-cell removal using BAR-T cells and jointly filed a related patent application.